Scope Biosciences has developed the scope Dx® platform, which utilizes proprietary type III CRISPR-Cas technology to deliver highly accurate molecular diagnostics. This innovative approach allows for the detection of nucleic acid sequences with exceptional specificity and sensitivity, making it suitable for various applications, including infectious disease diagnostics and genotyping. The technology combines isothermal LAMP amplification with CRISPR-Cas, enabling rapid amplification and readout of genetic material in under 30 minutes. This streamlined process is designed to be user-friendly, requiring minimal training and hardware, thus making it accessible for use in diverse settings.

The scope Dx® assay is particularly notable for its ability to detect even the smallest amounts of genetic material, including single nucleotide variations. This high level of sensitivity and specificity empowers users to make informed decisions on-site, without the need for a laboratory. The system's simple extraction process and one-pot reaction minimize reagent handling, enhancing reliability and ease of use. Overall, Scope Biosciences aims to revolutionize diagnostics by bringing advanced molecular testing capabilities directly to the point of need, thereby facilitating timely and accurate healthcare and agricultural solutions.

Netherlands

Develops the scopeDx ® platform, a technology that uses proprietary Type III CRISPR-Cas nucleases to detect nucleic acid sequences

Scope Biosciences

Company Details